Financial News
FibroGen, Inc - Common Stock (NQ: FGEN )
0.5545
+0.0337
(+6.47%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 14, 2025
Add to My Watchlist
All News about FibroGen, Inc - Common Stock
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/aapharma_1613.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/yesterdays_movers_271.png)
NASDAQ: FGEN Long Term Investor Alert: Investigation of Potential Wrongdoing at FibroGen, Inc.
August 20, 2021
Via SBWire
Topics
Lawsuit
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/medicine-1309148_1920_364.jpg)
Via Benzinga
Exposures
Product Safety
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/cells-1872666_1920_86.jpg)
Via Benzinga
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/mid-day_movers_image_1.jpg)
![](https://cdn2.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2021/analyst_ratings_image_35.jpeg?width=720)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/biotech2.jpg)
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
August 08, 2021
Via Benzinga
Exposures
Product Safety
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/aapharma_1558.png)
![](https://g.foolcdn.com/editorial/images/639640/doctor-discussing-with-elderly-man.jpg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/premkt_movers_431.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/peek_into_the_marketnew_243.png)
A Peek Into The Markets: US Stock Futures Down Ahead Of Earnings; Crude Oil Edges Lower
August 20, 2021
Via Benzinga
Exposures
Fossil Fuels
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/medicine-1309148_1920_365.jpg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/cells-1872666_1920_87.jpg)
Via Benzinga
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/medicine-1309148_1920_363.jpg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/dna-24559_1280_41.png)
Via Benzinga
Exposures
Product Safety
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/cells-1872666_1920_85.jpg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/aapharma_1432.png)
FibroGen Shares Are Trading Lower As FDA Shoots Down Roxadustat Application, Asks For Additional Trial
August 11, 2021
Via Benzinga
Exposures
Product Safety
![](https://cdn2.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/price_targets_249.png?width=720)
![](https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template.jpg)
FibroGen, inc (FGEN) Q2 2021 Earnings Call Transcript
August 10, 2021
Via The Motley Fool
Topics
Earnings
Exposures
Financial
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/sites/all/themes/bz2/images/bz-icon.png)
![](https://g.foolcdn.com/editorial/images/635480/gettyimages-1196964115.jpg)
Via The Motley Fool
Topics
Cannabis
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/cells-1872666_1920_82.jpg)
Via Benzinga
![](https://images.pexels.com/photos/2280549/pexels-photo-2280549.jpeg?auto=compress&cs=tinysrgb&h=750&w=1260)
Via Talk Markets
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/aapharma_1090.png)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/yesterdays_movers_246.png)
![](https://cdn.pixabay.com/photo/2018/07/15/10/44/dna-3539309_960_720.jpg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/medic-563423_1920_398_54.jpg)
![](https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/sites/all/themes/bz2/images/bz-icon.png)
Mid-Afternoon Market Update: Dow Tumbles Over 200 Points; Aehr Test Systems Shares Spike Higher
July 16, 2021
Via Benzinga
Topics
Stocks
Exposures
US Equities
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.